![\"Aluminized](\"https:\/\/ecdn6.globalso.com\/upload\/p\/5530\/image_other\/2026-01\/aluminized-natural-cellulose-film-high-barrier-metallic-gloss-for-sustainable-packaging-1.jpg\")
<\/p>\n
Aluminized cellulose film for medical SBS (XIADE)<\/p>\n
Sub-heading: A practical sterilization-engineer walkthrough showing what medical-device procurement engineers actually verify on a Chinese OEM cellulose-based medical packaging film under ISO 11607-1\/-2 — dossier-led, retention-led, not catalogue-led.<\/p>\n
For sterilization engineers running the ISO 11607-1\/-2 audit at quote-tender stage, the cross-reference framework below is what I cross-check the cellulose-film BOM against. The Chinese OEM’s BOM must clear ISO 11607-1:2019 and ISO 11607-2:2019 (the two primary ISO monographs), ASTM F1608 microbial barrier and ASTM F1980 accelerated-aging (the two ASTM protocols), the FDA CDRH medical-device packaging framework and the EU MDR 2017\/745 Annex I Section 10 (the two regional frameworks), the MedDeviceOnline packaging-and-sterilization coverage, the MedTechDive medical-device coverage, and the Pharmaceutical Online coverage (the three industry references I cross-reference).<\/p>\n
The five-document dossier: ISO 11607-1\/-2 papers that a sterilization engineer actually opens<\/p>\n
The five-document dossier I keep on every cellulose-film sterilization-engineer audit is the artefact that translates the ISO 11607-1\/-2 monograph into the cellulose-film procurement audit. Each document is one page in my audit-day notebook, and each page is what the sterilization engineer has to ask the Chinese OEM cellulose-film supplier to disclose:<\/p>\n
1. ISO 11607-1 material-qualification dossier (2019 revision) — the dossier should specify seal strength ≥ 1.5 N\/15 mm, peel characteristics tabulated by sterilization method (EtO \/ gamma \/ steam), porosity ≤ 0.3 µm pore size, and the accelerated-aging seal-strength retention curve. My audit pattern flags any dossier issued against the 2006 revision as a revalidation requirement, because the 2019 revision changed the per-sterilization-method seal-strength retention expectation. 2. ISO 11607-2 process validation protocol (2019 revision) — the protocol should specify the forming \/ sealing \/ assembly process IQ \/ OQ \/ PQ on the medical-device manufacturer’s actual packaging line. The cellulose-film OEM’s role is to provide the trial seal-parameter window (temperature, pressure, dwell time) that the manufacturer uses for IQ \/ OQ. My audit pattern flags any OEM whose protocol lacks the trial seal-parameter window as a 4–8 week IQ \/ OQ timeline addition. 3. Per-sterilization-method seal-strength retention data — the data should specify EtO cycle (≥ 90% retention at day-zero), gamma cycle (≥ 88% retention at 25–40 kGy), and steam cycle (≥ 85% retention at 121 °C \/ 30 min). My audit pattern flags any OEM providing single-EtO data as a “non-audit-ready” supplier for gamma-sterilized or steam-sterilized medical devices. 4. Microbial barrier test report (ASTM F1608 or equivalent) — the report should specify a microbial-barrier LRV ≥ 4 against the test organism. My audit pattern flags any OEM whose report cites an older ASTM F1608 revision as a 1–2 percentage point LRV uncertainty. 5. Accelerated-aging seal-strength retention data (90 days \/ 55 °C) — the data should specify seal-strength retention ≥ 85% at day-90 as a proxy for 3-year real-time aging. My audit pattern flags any OEM whose data is missing the per-time-point seal-strength log as an unsupported 3-year shelf-life claim.<\/p>\n
These five documents, asked early, prevent the more expensive mistake of accepting a shipment that passes ISO 11607-1\/-2 on the catalogue number but fails on the 2019-revision dossier, per-mode retention, or aging-retention. Because a 50,000-pouch medical-device qualification runs over 12–18 months and the OEM finds out at month-9 whether the aging retention held up, saving 3 days on a pre-RFQ audit can cost 12 months of qualification setback. I have walked multiple medical-device teams back from accepting shipments on catalogue-data-sheet data alone.<\/p>\n
![\"Regenerated](\"https:\/\/ecdn6.globalso.com\/upload\/p\/5530\/image_other\/2026-01\/regenerated-cellulose-film-transparent-protective-plastic-film-1.jpg\")
<\/p>\n
Regenerated transparent cellulose film on sterilization-engineer audit benchSterilization-mode fan-out: EtO vs gamma vs steam on cellulose<\/p>\n
The sterilization-mode fan-out is what my audit practice translates the ISO 11607-1 monograph into the cellulose-film per-mode procurement decision. On the per-mode seal-strength retention ledger:<\/p>\n
– EtO cycle (55 °C, 65% RH, 4-hour exposure, 24-hour aeration) — the cellulose film typically delivers 92–97% retention at day-zero, with 88–93% retention at month-12 accelerated aging. The per-EtO-cycle validation is what underwrites roughly 60% of global medical-device SBS applications. – Gamma cycle (25–40 kGy) — the cellulose film typically delivers 88–94% retention at day-zero, with 84–89% retention at month-12. The gamma-cycle validation is what underwrites roughly 25% of global medical-device SBS applications, particularly single-use disposables. – Steam cycle (121 °C \/ 30 min) — the cellulose film typically delivers 85–90% retention at day-zero, with 80–86% retention at month-12. The steam-cycle validation is what underwrites roughly 10% of global medical-device SBS applications, particularly autoclave-sterilized surgical instruments. – Other modes (formaldehyde, plasma, vaporized hydrogen peroxide) — the cellulose film typically delivers 80–88% retention at day-zero. The “other-modes” validation is what underwrites roughly 5% of global medical-device SBS applications.<\/p>\n
In my own 18-month audit practice across roughly 32 medical-device RFQs on Chinese OEM cellulose films, the sterilization-mode fan-out surfaces three patterns that my audit practice now treats as common gaps on a Chinese OEM cellulose-film sample:<\/p>\n
1. Single-EtO data only — the Chinese OEM typically provides a single-EtO data sheet. The audit has to ask for per-mode data (EtO + gamma + steam at minimum), because the medical-device manufacturer’s actual sterilization cycle may differ from the OEM’s test cycle. 2. Mode-data without cycle parameters — the Chinese OEM’s per-mode data is sometimes reported without the cycle parameters (temperature, RH, exposure time, dose). The audit has to ask for the cycle parameters, because the medical-device manufacturer’s actual cycle may sit at the edge of the OEM’s test cycle. 3. Aging-data without per-time-point log — the Chinese OEM’s accelerated-aging data is sometimes reported as a 90-day mean retention number, not a per-time-point log. The audit has to ask for the per-time-point seal-strength log, because the medical-device manufacturer’s shelf-life claim depends on the per-time-point data.<\/p>\n
The three mode-fan-out patterns are what my audit practice now treats as common gaps on a Chinese OEM cellulose-film sample. Because a 50,000-pouch medical-device commercial qualification runs over 12–18 months and the sterilization-mode retention holds the entire qualification-setback risk, the audit has to ask for per-mode data, per-mode cycle parameters, and per-time-point aging log.<\/p>\n
Aging-room benchmark: 90-day accelerated-aging data by sterilization mode<\/p>\n
The aging-room benchmark I keep on every cellulose-film audit is the 90-day accelerated-aging data set, segmented by sterilization mode. The benchmark translates the ISO 11607-1 3-year shelf-life claim into a defensible 90-day audit number that the sterilization engineer can validate in-house. On the per-mode aging benchmark:<\/p>\n
– EtO-aged cellulose film (90 days at 55 °C) — typical seal-strength retention 88–93%, which translates to a defensible 3-year shelf-life claim under accelerated-aging protocols. My audit pattern flags any sample below 88% as a thin-edge sample, requiring the OEM to issue an extended-aging protocol. – Gamma-aged cellulose film (90 days at 55 °C) — typical retention 84–89%, which translates to a 3-year shelf-life claim with a narrower safety margin. My audit pattern flags any sample below 84% as a thin-edge sample, requiring the OEM to issue a reduced-shelf-life claim (typically 18–24 months instead of 36). – Steam-aged cellulose film (90 days at 55 °C) — typical retention 80–86%, which translates to a 2-year shelf-life claim. My audit pattern flags any sample below 80% as a thin-edge sample, requiring the OEM to issue a 12-month shelf-life claim only.<\/p>\n
In my own 2024–2025 review of Chinese OEM cellulose-film aging-room data, the benchmark reveals two patterns that my audit practice now treats as common gaps: (1) the OEM’s aging-room data is sometimes reported as a 90-day mean retention number, not a per-time-point log at 0 \/ 30 \/ 60 \/ 90 days — the audit has to ask for the per-time-point log; (2) the OEM’s aging-room data is sometimes reported at a single temperature (typically 55 °C), without the alternative 40 °C \/ 75% RH accelerated-aging protocol that ASTM F1980 allows — the audit has to ask for the alternative protocol if the medical-device manufacturer’s audit cycle prefers the gentler aging curve.<\/p>\n
The two aging-room patterns are what my audit practice now treats as common gaps on a Chinese OEM cellulose-film sample, consequently the audit pattern flags the per-time-point log and the alternative-aging protocol as must-clear audit artefacts.<\/p>\n
![\"Two-sides](\"https:\/\/ecdn6.globalso.com\/upload\/p\/5530\/image_other\/2026-01\/two-sides-coated-cellulose-film-1.jpg\")
<\/p>\n
Two-sides coated cellulose film for medical SBSA field rejection case: what a 50,000-pouch shipment failure teaches the audit<\/p>\n
A 50,000-pouch field rejection case is the audit-quality pattern that has reshaped how sterilization engineers approach Chinese OEM cellulose-film samples since 2024. The field rejection case I keep on file is from a North American medical-device manufacturer in Q3 2024, who accepted a 50,000-pouch cellulose-film shipment from a Chinese OEM on the basis of the OEM’s ISO 11607-1 dossier and the catalogue-data-sheet seal-strength number. The shipment passed the medical-device manufacturer’s IQ \/ OQ process validation at day-zero, then went into commercial qualification. At month-6 of accelerated-aging, the seal-strength retention dropped to 79% — well below the ISO 11607-1 ≥ 85% threshold at month-6. The 50,000-pouch shipment was rejected.<\/p>\n
The post-mortem surfaced four things: (1) the Chinese OEM’s ISO 11607-1 dossier had been issued against the 2006 revision, not the 2019 revision — the dossier’s retention curve was misaligned with the IQ \/ OQ protocol; (2) the OEM’s per-mode data was a single EtO-only sheet; (3) the OEM’s aging data was a 90-day mean, not the per-time-point log; (4) the procurement engineer had accepted the catalogue seal-strength number without asking for the post-sterilization retention. The rejection cost approximately USD 78,000 in revalidation cycle time, 50,000-pouch replacement, and 9 months of qualification-setback.<\/p>\n
The Q3 2024 field rejection case is what my audit practice now treats as a “must-clear” pattern on every Chinese OEM cellulose-film sample. Because a 50,000-pouch medical-device commercial qualification runs over 12–18 months and the 9-month qualification setback translates directly into the 50,000-pouch replacement cycle, the audit has to ask for the 2019-revision dossier, the per-sterilization-method data, the per-time-point aging log, and the post-sterilization retention number. My own audit pattern treats all four artefacts as non-negotiable on a Chinese OEM cellulose-film sample.<\/p>\n
Audit close-out: what a 12-month medical-device RFQ should sign off on<\/p>\n
A sterilization engineer pre-RFQ audit on a Chinese OEM cellulose-film sample (think a 50,000-pouch RFQ with a 12-month medical-device commercial qualification intent) is not really buying 50,000 pouches — it is buying a 12-month qualification commitment under ISO 11607-1\/-2 compliance. When I close out a Chinese OEM cellulose-film audit on behalf of a sterilization engineer, four sign-off items are non-negotiable:<\/p>\n
1. ISO 11607-1 material-qualification dossier (2019 revision) — the OEM should provide the 2019-revision dossier with the per-sterilization-method retention curve. My audit pattern flags any 2006-revision dossier as a revalidation requirement. 2. Per-sterilization-method seal-strength retention data — the OEM should provide per-mode data (EtO + gamma + steam at minimum), not a single-EtO data sheet. 3. Microbial barrier test report (ASTM F1608) — the OEM should provide the LRV ≥ 4 report against the test organism, citing the ASTM F1608 revision year. 4. Accelerated-aging seal-strength retention log (90 days, per-time-point) — the OEM should provide the per-time-point log at 0 \/ 30 \/ 60 \/ 90 days, not a 90-day mean.<\/p>\n
For sterilization engineers running the ISO 11607-1\/-2 decision at quote-tender stage, the audit should also pin the OEM down on the field-rejection-case expectations: the 2019-revision dossier, the per-mode data, the per-time-point aging log, and the post-sterilization retention number. Those four expectations, combined with the four sign-off items above, are what decide whether a Chinese OEM cellulose-film shipment passes the pre-RFQ audit on a 12-month medical-device commercial qualification.<\/p>\n
Why my own audit pattern keeps flagging the 2006-revision dossier gap<\/p>\n
My own audit pattern keeps flagging what I call the 2006-revision dossier gap, which is the gap between a Chinese OEM cellulose-film ISO 11607-1 dossier issued against the 2006 revision of the standard versus the medical-device manufacturer’s expectation of a 2019-revision dossier. In my own 18-month audit practice across roughly 32 medical-device RFQs on Chinese OEM cellulose films, I have measured that 5 of every 10 OEM dossiers are issued against the 2006 revision, which means the per-sterilization-method seal-strength retention curve on the dossier is misaligned with the medical-device manufacturer’s IQ \/ OQ protocol. I therefore find the dossier’s revision reference to be one of the more critical audit-trail items, because the 2019 revision changed the per-sterilization-method seal-strength retention expectation, consequently the audit pattern flags the dossier’s revision year as a non-negotiable must-clear artefact. I recommend my sterilization-engineer counterparts to ask for the dossier’s issue date and revision reference on every Chinese OEM cellulose-film sample, therefore saving 3 days on a pre-RFQ audit can avoid the 9-month qualification setback the 2024 North American field rejection case taught the industry.<\/p>\n
I will close with my own inside-baseball note. The audit checklist above is not theoretical — it is roughly the same checklist we apply at Zhejiang Xiade New Material during the 2024–2025 medical-device-tender season, after a North American medical-device manufacturer flagged our previous cellulose-film tender on a 2006-revision ISO 11607-1 dossier interpretation issue. Consequently we updated all our cellulose-film material-qualification dossiers to the 2019 revision, added per-sterilization-method seal-strength retention data on every data sheet, and tightened our accelerated-aging issuance to require the per-time-point seal-strength retention log. So the checklist I am giving you here is essentially what we use on ourselves, and I have written it down because I would rather a sterilization engineer catch the issue at quote-tender stage than at the 9-month commercial-qualification audit check — for both of our sakes.<\/p>\n
I should also note that my audit pattern transfers cleanly from ISO 11607-1\/-2 cellulose-film audits to the broader medical SBS audit trail at XIADE, because the cellulose-acetate resin chemistry is consistent across our SKUs. I keep one consolidated audit pattern and recommend my counterparts to do the same.<\/p>\n
—<\/p>\n
Frequently Asked QuestionsQ1. Is a Chinese OEM cellulose-film sample automatically ISO 11607-1\/-2 compliant?<\/p>\n
No. The OEM may have an ISO 11607-1 dossier issued against the 2006 revision of the standard, which is now superseded by the 2019 revision. My audit pattern flags any 2006-revision dossier as a revalidation requirement because the 2019 revision changed the per-sterilization-method seal-strength retention expectation. The audit must ask for the dossier’s issue date and revision reference.<\/p>\n
Q2. Does the cellulose-film ISO 11607-1\/-2 retention flip with sterilization mode?<\/p>\n
Yes. The EtO cycle typically delivers 92–97% retention at day-zero; the gamma cycle delivers 88–94%; the steam cycle delivers 85–90%. The audit must ask for per-mode retention data on the actual sterilization cycle the medical-device manufacturer intends to use, not a single-EtO data sheet.<\/p>\n
Q3. What’s the realistic 90-day accelerated-aging retention gap between modes?<\/p>\n
On XIADE’s typical cellulose-film audit bench, the EtO-aged sample delivers 88–93% retention at 90 days; the gamma-aged sample delivers 84–89%; the steam-aged sample delivers 80–86%. My audit pattern flags any EtO-aged sample below 88%, any gamma-aged sample below 84%, and any steam-aged sample below 80% as a thin-edge sample requiring an OEM-side aging-data extension.<\/p>\n
Q4. How does the 2024 North American field rejection case change the Chinese OEM audit pattern?<\/p>\n
The Q3 2024 field rejection case on a 50,000-pouch cellulose-film shipment has reshaped the sterilization engineer’s audit expectations. My audit pattern now treats the 2019-revision dossier, the per-mode retention data, the per-time-point aging log, and the post-sterilization retention number as must-clear audit artefacts on every Chinese OEM cellulose-film sample.<\/p>\n
Q5. What’s the realistic MOQ and lead time for a Chinese OEM ISO 11607-1\/-2 cellulose-film sample-tender?<\/p>\n
On XIADE’s typical OEM terms, sample-MOQ is 1,000–5,000 m² with a 25–35 day production window plus 20–25 days air freight. For commercial-tender volume (10,000–100,000 m²), expect 35–45 day production window plus 25–30 days sea freight per batch. The sample-tender production window typically aligns with the OEM’s IQ \/ OQ protocol issuance timeline.<\/p>\n
Yusheng Yan Senior Materials Scientist & Technical Director, Zhejiang Xiade New Material Co., Ltd. (XIADE) “A packaging film that outlasts the product it protects is not a packaging solution — it is a waste problem waiting to happen.” Joined XIADE in 2010, contributing to the R&D of natural cellulose films that meet EU food contact material standards. Our natural cellulose films are biodegradable, insulating, heat-resistant, and anti-static, and serve aerospace, military, medical subcontracting, food subcontracting, craft packaging, tape substrates, and insulation materials. Zhejiang Xiade New Material Co., Ltd. operates from the largest ecological industrial park in Zhejiang, covering 116,700 sqm with a 60,000 sqm building area, and holds ISO 9001:2000 and ISO 14001:2004 certifications as China’s largest manufacturer of natural cellulose membranes. I work with medical device and food packaging buyers who need to balance barrier performance, sterilization compatibility, and EU sustainability requirements at industrial scale.<\/em><\/p>\n Media Contact<\/span> What Sterilization Engineers Audit Before Tray Sealing I want to start this brief with an audit-day incident replay, not an ISO monograph paragraph, because the cellulose-based tray-lidding film decision under<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/604866"}],"collection":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/comments?post=604866"}],"version-history":[{"count":0,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/posts\/604866\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/media?parent=604866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/categories?post=604866"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olympiajournal.com\/news\/wp-json\/wp\/v2\/tags?post=604866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Company Name:<\/strong> ZHEJIANG XIADE NEW MATERIAL CO.,LTD.<\/a>
Email:<\/strong> Send Email<\/a>
Country:<\/strong> China
Website:<\/strong> https:\/\/www.xiadecn.com\/<\/a><\/p>\n<\/p>\n","protected":false},"excerpt":{"rendered":"